Literature DB >> 25964634

Defining borderline resectable pancreatic cancer: emerging consensus for an old challenge.

Mokenge P Malafa.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25964634     DOI： 10.6004/jnccn.2015.0068

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  7 in total

1.  Anti-α-enolase antibody limits the invasion of myeloid-derived suppressor cells and attenuates their restraining effector T cell response.

Authors:  Paola Cappello; Elisabetta Tonoli; Roberta Curto; Daniele Giordano; Mirella Giovarelli; Francesco Novelli
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

2.  CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer.

Authors:  Jennifer L Williams; Brian E Kadera; Andrew H Nguyen; V Raman Muthusamy; Zev A Wainberg; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2016-04-25       Impact factor: 3.452

3.  Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Rahul V Parghane; Manish Bhandare; Vikram Chaudhari; Vikas Ostwal; Anant Ramaswamy; Sanjay Talole; Shailesh V Shrikhande; Sandip Basu
Journal:  J Nucl Med       Date:  2021-02-26       Impact factor: 10.057

Review 4.  Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.

Authors:  Trond A Buanes
Journal:  World J Gastroenterol       Date:  2016-12-28       Impact factor: 5.742

Review 5.  Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits.

Authors:  Stefan Heinrich; Hauke Lang
Journal:  Int J Mol Sci       Date:  2017-07-26       Impact factor: 5.923

Review 6.  Next Generation Immunotherapy for Pancreatic Cancer: DNA Vaccination is Seeking New Combo Partners.

Authors:  Paola Cappello; Claudia Curcio; Giorgia Mandili; Cecilia Roux; Sara Bulfamante; Francesco Novelli
Journal:  Cancers (Basel)       Date:  2018-02-16       Impact factor: 6.639

7.  Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.

Authors:  Chenwi M Ambe; Phuong Nguyen; Barbara A Centeno; Junsung Choi; Jonathan Strosberg; Larry Kvols; Pamela Hodul; Sarah Hoffe; Mokenge P Malafa
Journal:  Cancer Control       Date:  2017 Oct-Dec       Impact factor: 3.302
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.